Clinical Implications of Circulating Tumor Cells in Pediatric ATRT Progression Forecasting

Overview

This study evaluated the feasibility and clinical predictive value of detecting circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) and peripheral blood of pediatric patients with atypical teratoid rhabdoid tumor (ATRT). Findings suggest that CTC quantification may serve as a valuable biomarker for early detection of tumor progression in children under 3 years undergoing comprehensive treatment.

Background

Atypical teratoid rhabdoid tumor (ATRT) is a rare, highly malignant CNS tumor predominantly affecting children under 3 years old. Standard treatment involves surgery, high-dose chemotherapy, and radiotherapy, though radiotherapy is often deferred due to neurocognitive risks. Early prediction of metastasis and tumor progression is critical for optimizing treatment strategies. Circulating tumor cells (CTCs) have shown prognostic value in various solid tumors but remain understudied in pediatric CNS tumors, particularly ATRT.

Data Highlights

Key Findings

• CTCs were successfully detected and quantified in both CSF and peripheral blood samples of pediatric ATRT patients using an integrated microfluidic system and cascaded filter deterministic lateral displacement microchips.
• Two morphological types of CTCs were identified: pure tumor cells (CD45-/CK+ or BCL-xL+/DAPI+) and circulating hybrid cells (CD45+/CK+ or BCL-xL+/DAPI+).
• CTC counts correlated with tumor progression assessed by MRI and CSF cytology, showing potential as an early biomarker for disease monitoring.
• Receiver operating characteristic (ROC) analysis was used to define thresholds for CTC counts predictive of tumor progression.
• Kappa coefficient analysis demonstrated agreement between CTC detection and established progression assessment methods, supporting clinical utility.

Clinical Implications

Quantification of CTCs in CSF and peripheral blood offers a minimally invasive method to monitor ATRT progression in young children, potentially enabling earlier intervention. Incorporating CTC analysis into routine clinical assessment may improve prognostic accuracy and guide treatment adjustments, particularly when radiologic or cytologic findings are inconclusive.

Conclusion

This study supports the feasibility and clinical relevance of CTC detection in pediatric ATRT patients as a predictive biomarker for tumor progression. Further research with larger cohorts is warranted to validate these findings and integrate CTC monitoring into standard care protocols.

References

1. 1 -- ATRT clinical characteristics and epidemiology
2. 2,3 -- Standard treatment approaches for ATRT
3. 4,5 -- Radiotherapy considerations in pediatric ATRT
4. 7 -- Importance of early metastasis prediction in malignant tumors
5. 8 -- Role of circulating tumor cells in metastasis
6. 9-13 -- Prognostic value of CTCs in solid and brain tumors
7. 14 -- RAPNO committee response assessment guidelines
8. 15-18 -- Microfluidic systems and CFD-Chip technology for CTC enrichment